SCHEMBL5579221

SCHEMBL5579221

OCCCOc1ccc2oc3ccccc3c2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.62
ACSL1 P33121 2/20 0.56
ACSL6 Q9UKU0 2/20 0.56
MAPT P10636 3/20 0.54
NPC1 O15118 2/20 0.54
ALDH1A1 P00352 2/20 0.50
PTGER4 P35408 1/20 0.50
MAOB P27338 6/20 0.48
HRH3 Q9Y5N1 6/20 0.48
BCHE P06276 1/20 0.48
ACHE P22303 1/20 0.48
HPGD P15428 2/20 0.47
POLB P06746 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
XDH P47989 2/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10090415 0.92 LMNA (0.64) LMNAACSL1ACSL6MAPTNPC1
SCHEMBL9870777 0.86 LMNA (0.60) LMNAACSL1ACSL6MAPTNPC1
SCHEMBL5390554 0.84 LMNA (0.58) LMNAACSL1ACSL6MAPTNPC1
SCHEMBL16806176 0.83 LMNA (0.60) LMNAACSL1ACSL6MAPTNPC1
SCHEMBL10090173 0.83 LMNA (0.60) LMNAACSL1ACSL6MAPTNPC1
SCHEMBL30748196 0.82 XDH (0.67) ACSL1ACSL6NPC1BCHEACHE
SCHEMBL7812629 0.82 ACSL1 (0.77) LMNAACSL1ACSL6MAPTNPC1
SCHEMBL7405337 0.82 ACSL1 (0.56) LMNAACSL1ACSL6MAPTNPC1
SCHEMBL7397081 0.82 ACSL1 (0.56) LMNAACSL1ACSL6MAPTNPC1
SCHEMBL10090166 0.81 LMNA (0.61) LMNAACSL1ACSL6MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 US disclosed
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 US disclosed
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 US disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 US disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 US disclosed
EP-0708767-B1 HAPTENS, TRACERS, IMMUNOGENS AND ANTIBODIES FOR CARBAZOLE AND DIBENZOFURAN DERIVATIVES ABBOTT LAB (US) 2001-02-14 EP disclosed
EP-0708767-A4 HAPTENS, TRACERS, IMMUNOGENS AND ANTIBODIES FOR CARBAZOLE AND DIBENZOFURAN DERIVATIVES ABBOTT LAB (US) 1996-10-02 EP disclosed
US-5541333-A TETHERED HAPTEN INTERMEDIATES ABBOTT LABORATORIES (US) 1996-07-30 US disclosed
EP-0708767-A1 HAPTENS, TRACERS, IMMUNOGENS AND ANTIBODIES FOR CARBAZOLE AND DIBENZOFURAN DERIVATIVES ABBOTT LABORATORIES (US) 1996-05-01 EP disclosed
US-5464746-A Haptens, tracers, immunogens and antibodies for carbazole and dibenzofuran derivatives ABBOTT LABORATORIES (US) 1995-11-07 US disclosed
WO-1995003296-A1 HAPTENS, TRACERS, IMMUNOGENS AND ANTIBODIES FOR CARBAZOLE AND DIBENZOFURAN DERIVATIVES ABBOTT LABORATORIES (US) 1995-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors PPARG, NCOA4, PPARA LMNA 4004/4885ACSL1 287/4885ACSL6 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.